J
Juergen Braun
Researcher at Ruhr University Bochum
Publications - 113
Citations - 4805
Juergen Braun is an academic researcher from Ruhr University Bochum. The author has contributed to research in topics: Ankylosing spondylitis & Psoriatic arthritis. The author has an hindex of 34, co-authored 113 publications receiving 3935 citations. Previous affiliations of Juergen Braun include Leiden University Medical Center.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B. McInnes,Joachim Sieper,Juergen Braun,Paul Emery,Désirée van der Heijde,John D. Isaacs,Georg Dahmen,Jürgen Wollenhaupt,Hendrik Schulze-Koops,Joseph Kogan,Shenglin Ma,Martin Schumacher,Arthur P. Bertolino,Wolfgang Hueber,Paul P. Tak,Paul P. Tak +15 more
TL;DR: Although the primary endpoint was not met, clinical responses, acute-phase reactant and quality of life improvements were greater with secukinumab versus placebo, suggesting some clinical benefit.
Journal ArticleDOI
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative
Laure Gossec,Maarten de Wit,Uta Kiltz,Juergen Braun,Umut Kalyoncu,Rossana Scrivo,Mara Maccarone,L. Carton,Kati Otsa,Imre Sooäär,Turid Heiberg,Heidi Bertheussen,Juan D. Cañete,Anselm Sánchez Lombarte,Andra Balanescu,Alina Dinte,Kurt de Vlam,Josef S Smolen,Tanja Stamm,Dora Niedermayer,Gabor Békés,Douglas J. Veale,Philip S. Helliwell,Andrew Parkinson,Thomas A. Luger,Tore K Kvien +25 more
TL;DR: A questionnaire to assess the impact of PsA on patients’ lives has been developed and validated and should allow better assessment of the patient's perspective in PsA.
Journal ArticleDOI
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Xenofon Baraliakos,Joachim Listing,J Brandt,Angela Zink,Rieke Alten,Gerd R Burmester,E Gromnica-Ihle,Herbert Kellner,Matthias Schneider,H. Sörensen,Henning Zeidler,Martin Rudwaleit,Joachim Sieper,Juergen Braun +13 more
TL;DR: Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one and patients who were in partial remission according to the ASAS criteria and those with normal C-reactive protein levels at the time point of withdrawal had longer times to relapse after discontinuation of the treatment.
Journal ArticleDOI
Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis
Pedro Machado,Robert Landewé,Juergen Braun,Kay-Geert A. Hermann,Daniel Baker,Désirée van der Heijde +5 more
TL;DR: Spinal mobility impairment in AS is independently determined both by irreversible spinal damage and by reversible spinal inflammation, as assessed by MRI in patients with ankylosing spondylitis.
Journal ArticleDOI
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
TL;DR: These findings obtained in patients treated with anti-tumour necrosis factor (anti-TNF) agents suggest linkage and some dissociation of inflammation and new bone formation in ankylosing spondylitis.